In general the role of PAR2 in producing obesity, diabetes, and metabolic syndrome has been investigated entirely independent of the function of the vascular system and supports the development of pharmaceutical antagonists of PAR2. This evidence concerns the gene F2RL1 and obesity due to melanocortin 4 receptor deficiency.